{
    "nctId": "NCT00003906",
    "briefTitle": "Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women",
    "officialTitle": "Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 19747,
    "primaryOutcomeMeasure": "Incidence of invasive breast cancer; superiority of one of the therapies.",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Postmenopausal women at increased risk for developing invasive breast cancer, who meet one of the following criteria:\n\n  * At least 12 months since spontaneous menstrual bleeding\n  * Prior documented hysterectomy and bilateral salpingo-oophorectomy\n  * At least 55 years of age with prior hysterectomy with or without oophorectomy\n  * Age 35 to 54 with a prior hysterectomy without oophorectomy OR with a status of ovaries unknown with documented follicle-stimulating hormone level demonstrating elevation in postmenopausal range\n* Histologically confirmed lobular carcinoma in situ treated by local excision only OR a minimum projected 5 year probability of invasive breast cancer of at least 1.66%, using Breast Cancer Risk Assessment Profile\n* No clinical evidence of malignancy on physical exam within the past 180 days\n* No evidence of suspicious or malignant disease on bilateral mammogram within the past year\n* No bilateral or unilateral prophylactic mastectomy\n* No prior invasive breast cancer or intraductal carcinoma in situ\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 35 and over\n\nSex:\n\n* Female\n\nMenopausal status:\n\n* See Disease Characteristics\n\nPerformance status:\n\n* No restricted normal activity for a significant portion of each day\n\nLife expectancy:\n\n* At least 10 years\n\nHematopoietic:\n\n* Granulocyte count at least 1,500/mm\\^3\n* Complete blood count and differential normal\n* Platelet count normal\n\nHepatic:\n\n* SGOT or SGPT normal\n* Bilirubin normal\n* Alkaline phosphatase normal\n\nRenal:\n\n* Creatinine normal\n\nCardiovascular:\n\n* No cerebral vascular accident, transient ischemic attack, atrial fibrillation, or uncontrolled hypertension\n* No deep vein thrombosis\n\nPulmonary:\n\n* No pulmonary embolus\n\nOther:\n\n* No other prior malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* No concurrent nonmalignant disease that would preclude administration of tamoxifen or raloxifene\n* No clinical depression, psychiatric condition, or addictive disorder\n* No uncontrolled diabetes\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* Not specified\n\nChemotherapy:\n\n* Not specified\n\nEndocrine therapy:\n\n* At least 3 months since prior estrogen or progesterone replacement therapy, oral contraceptives, androgens, luteinizing hormone-releasing hormone analogs, prolactin inhibitors, or antiandrogens\n* At least 3 months since prior tamoxifen, raloxifene, or other selective estrogen-receptor modulators of less than 3 months duration\n* Concurrent Estring allowed\n\nRadiotherapy:\n\n* No prior breast radiotherapy\n\nSurgery:\n\n* See Disease Characteristics\n\nOther:\n\n* No prior systemic adjuvant therapy for breast cancer\n* No other participation in a cancer prevention or osteoporosis prevention study involving pharmacologic intervention(s)\n\n  * NSABP-P-1 patients who received placebo are eligible\n* No concurrent warfarin or cholestyramine\n* Concurrent calcitonin or nonhormonal medication (e.g., cholecalciferol, fluoride, or bisphosphonates) allowed",
    "sex": "FEMALE",
    "minimumAge": "35 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}